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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder that often persists
into adulthood. There is growing evidence that epigenetic dysregulation participates in ADHD. Given that only a
limited number of epigenome-wide association studies (EWASs) of ADHD have been conducted so far and they have
mainly focused on pediatric and population-based samples, we performed an EWAS in a clinical sample of adults with
ADHD. We report one CpG site and four regions differentially methylated between patients and controls, which are
located in or near genes previously involved in autoimmune diseases, cancer or neuroticism. Our sensitivity analyses
indicate that smoking status is not responsible for these results and that polygenic risk burden for ADHD does not
greatly impact the signatures identified. Additionally, we show an overlap of our EWAS findings with genetic
signatures previously described for ADHD and with epigenetic signatures for smoking behavior and maternal smoking.
These findings support a role of DNA methylation in ADHD and emphasize the need for additional efforts in larger
samples to clarify the role of epigenetic mechanisms on ADHD across the lifespan.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder characterized by
age-inappropriate levels of inattention, impulsivity and
hyperactivity1. ADHD is a disabling condition in child-
hood and adolescence which often persists into adult-
hood, interfering with the quality of social, academic, or
occupational functioning2,3.
ADHD is a multifactorial disorder with an estimated
heritability of 76%. Twenty-two percent of its phenotypic
variance is explained by common genetic variants1,4 and
the proportion of variance still to be explained might be,
to some extent, accounted for by gene by environment
interactions. In this context, epigenetic processes have
emerged as a plausible mechanism by which environ-
mental exposures can lead to long-lasting alterations, such
as variation in brain structure or neuronal circuits, found
in psychiatric disorders5–7. There is growing evidence that
epigenetic dysregulation is a feature of ADHD6,8–11,
depression12, autism13–16, schizophrenia17,18 and bipolar
disorder19.
Studies of DNA methylation profiles in ADHD have been
conducted using peripheral blood, cord blood, buccal
samples or saliva6,9–11,20–28. Candidate gene studies have
revealed differential methylation patterns in genes involved
in the dopaminergic, serotoninergic and neurotrophic
systems, including SLC6A4, DRD4, COMT, ANKK1,
BDNF, or NGFR, associated with ADHD symptomatology
and severity23–28. Seven epigenome-wide association stu-
dies (EWASs) on ADHD have been run to date, with
sample sizes ranging from 54 subjects for clinical samples21
to 4,689 individuals in a meta-analysis considering ADHD
symptomatology in general population9, yielding non-
overlapping findings across them6,9–11,20–22. There is
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limited research on adults using this approach, given that
most of the EWASs have focused on pediatric sam-
ples6,10,11,20,22. To the best of our knowledge, only two
studies evaluated methylome-wide patterns on adults9,21.
One identified methylation changes associated with ADHD
symptomatology that did not remain significant when
results were meta-analyzed across cohorts9. The second
one found hypermethylated regions in genes involved in
fatty acid metabolism and fatty acid oxidation pathways
associated with ADHD persistence when compared to
remittance21. In the childhood period, Wilmot et al. ana-
lyzed a population cohort of school-age boys and found
lower methylation levels at the VIPR2 gene in ADHD
subjects compared to their age- and sex- matched con-
trols10, results that were recently replicated in the largest
EWAS on ADHD in children conducted so far22. In a
similar aged population cohort, Walton et al. investigated
ADHD symptom trajectories from birth to adolescence
and pointed to epigenetic marks in genes related to neural
tube development and peroxisomal mechanisms as candi-
dates to be involved in the different ADHD symptom
trajectories across time6. In the most recent EWAS eval-
uating ADHD symptoms in population-based cohorts,
aberrant methylation patterns at birth in different regions,
lying in the ERC2 and CREB5 genes among others, were
associated with later ADHD symptoms in childhood or
adolescence11. And finally, the latest and largest EWAS
conducted in a clinical sample of children with ADHD
supported the association between ADHD polygenic risk
and DNA methylation patterns at the GART and SON
genes22.
Recent evidence supports a large genetic overlap between
ADHD in children and adults29, but little is known about
the co-occurrence between the epigenetic signatures
characterizing both groups of age. In addition, although
various studies report shared genetics between ADHD and
several psychiatric and behavioral traits4,29, this overlap has
not been assessed yet using epigenome-wide data.
Whereas most previous studies considered pediatric
clinical samples or adult population-based cohorts with
measures of ADHD symptoms, we report an EWAS on a
clinical sample of adults with ADHD. With these data we
(i) assessed DNA methylation signatures for ADHD in
adults through an EWAS in peripheral blood mono-
nuclear cells, (ii) tested whether either polygenic risk
burden for ADHD or smoking status had an impact on
those DNA methylation signatures, (iii) examined whe-
ther exposure to stressful life events had an effect on these
methylation patterns in ADHD subjects and (iv) explored
the overlap between these findings and results from pre-
vious meta-analyses of genome-wide association studies
(GWAS-MA) on clinical ADHD or ADHD symptoms in
population-based samples, and EWAS on ADHD symp-
toms or exposure to stressful life events.
Materials and methods
Participants and clinical assessment
The clinical sample consisted of 103 ADHD subjects
that were referred to an ADHD program from primary
care centers and adult community mental health services.
All subjects were evaluated and recruited prospectively
from a restricted geographic area of Catalonia (Spain) in a
specialized out-patient program for Adult ADHD and by
a single clinical group at Hospital Universitari Vall
d’Hebron of Barcelona (Spain).
The clinical assessment consisted of structured inter-
views and self-reported questionnaires in two different
steps: (i) assessment of ADHD diagnosis based on
symptomatology using the Conner’s Adult ADHD
Diagnostic Interview for DSM-IV (CAADID) by a psy-
chiatrist and, (ii) assessment of the severity of ADHD
symptoms, the levels of impairment and the presence of
comorbid disorders by a psychologist to increase the
diagnostic accuracy and reduce the likelihood of mis-
diagnosis with the Conners ADHD Rating Scale
(CAARS), the ADHD Rating Scale (ADHD-RS), the
Clinical Global Impression (CGI), the Wender Utah
Rating Scale (WURS), the Sheehan Disability Inventory
(SDS), and the Structured Clinical Interview for DSM-IV
Axis I and II Disorders (SCID-I and SCID-II). After-
wards, the psychiatrist and psychologist integrate the
clinical information and self-reports for the valid
assessment of symptoms and impairments. In case of
discordance between different raters of ADHD symp-
toms or inconsistencies between reporters in responses
to items measuring similar symptoms, the clinician-
identified symptoms on the CAADID prevailed. Exclu-
sion criteria were IQ < 70; lifelong and current history of
mood, psychotic, anxiety, substance abuse, and DSM-IV
axis II disorders; pervasive developmental disorders; a
history or the current presence of a condition or illness,
including neurologic, metabolic, cardiac, liver, kidney, or
respiratory disease; a chronic medication of any kind;
birth weight≤1.5 kg; and other neurological or systemic
disorders that might explain ADHD symptoms. For
more detailed information on clinical assessment see
Sánchez-Mora et al.30.
Data pertaining to exposure to 17 stressful life events
(six gestational and 11 postnatal) were collected retro-
spectively with the CAADID Part I31 and were available
from 98 subjects with ADHD. No information was
available from controls. Specifically, this questionnaire
includes: premature birth, illegal drug abuse during
pregnancy, maternal smoking, prenatal exposure to drugs,
maternal health problems during pregnancy, other pro-
blems during maternal pregnancy, exposure to heavy
metals, malnutrition, financial stress and/or poverty,
extreme familial stress, neglect, familiar violence, emo-
tional and physical maltreatment, sexual abuse, death or
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separation from a loved one, and other trauma in child-
hood or adolescence.
The control sample consisted of 100 unrelated healthy
blood donors matched by sex and ethnicity with the
clinical group. Individuals with ADHD symptomatology
were excluded retrospectively under the following criteria:
(1) having been diagnosed with ADHD previously or (2)
answering positively to the lifetime presence of the fol-
lowing ADHD symptoms: (a) often has trouble in keeping
attention on tasks, (b) usually loses things needed for
tasks, (c) often fidgets with hands or feet or squirms in
seat, and (d) often gets up from seat when remaining in
seat is expected.
All subjects reported European ancestry, which was
confirmed through principal component analysis (PCA)
using genetic data. The study was approved by the Clinical
Research Ethics Committee (CREC) of Hospital Uni-
versitari Vall d’Hebron, all methods were performed in
accordance to the relevant guidelines and regulations and
written informed consent was obtained from all subjects
before inclusion into the study.
DNA isolation, quantification, and genome-wide DNA
methylation assays
Peripheral blood mononuclear cells (PBMCs) of
patients with ADHD and controls were isolated using the
Ficoll density gradient method, and DNA was extracted
using the QIAamp DNA Mini Kit DNA Purification fol-
lowing manufacturer’s instructions (Qiagen, Hilden,
Germany). The quality of the samples was checked by
NanoDrop® ND-1000 (Thermo Fisher Scientific, MA)
and by PicoGreen® (Thermo Fisher Scientific, MA).
Genome-wide DNA methylation was assessed with the
Illumina Infinium MethylationEPIC BeadChip Kit (EPIC
array) (Illumina, San Diego, CA, USA) following sodium
bisulfite treatment of genomic DNA.
DNA methylation analysis based on ADHD diagnosis
Data preprocessing and normalization
The 203 samples included in this study were assayed in
three batches, which were preprocessed and normalized
separately. Raw signal intensities of each probe were
extracted using the Illumina Genome Studio software
(https://support.illumina.com) and were imported into
the R software (3.6.0 version; https://www.R-project.org)
using the minfiData 0.2 package32. The bisulfite conver-
sion control probes and the 59 single nucleotide poly-
morphism (SNP) probes of the EPIC array were used to
calculate the bisulfite conversion reaction efficiency and
to confirm the absence of sample contamination,
respectively. Sex was confirmed for all samples using the
getSex function of the minfi R package33. The Horvath
Epigenetic Clock algorithm34 implemented by the agep
function of the wateRmelon R package was used to
calculate the estimated age of participants according to
their DNA methylation data, which correlated with their
reported age (ρ= 0.82, SE= 0.04, P < 2.00E−16). Poorly
performing probes or samples were removed using the
wateRmelon R package (version 0.9.9;35). The exclusion
criteria for the probes included detection P-values >0.05
for >1% of the samples and a beadcount <3 for >5% of the
samples. Probes that were cross-reactive, present in sexual
chromosomes or that contained polymorphisms were also
excluded from the study36,37. Samples with >1% of probes
with a detection P-value >0.01 were also removed. Probes
that passed the quality control filters were quantile nor-
malized with the dasen function of the wateRmelon
R package.
Bioinformatic and statistical analyses
PCA of methylation values was conducted using the
prcomp function of the stats R package, first separately for
each batch and then across all batches. Within batch,
non-biological experimental variation (Sentrix Position
and chip ID) of normalized methylation values was tested
for association with the Principal Component loadings
(PCs). Chip ID was associated with the first PC (PC1) in
all three batches, which accounted for the 99% of the
variation of samples. We therefore adjusted the beta
values with the ComBat function of the SVA R package38
for this variable. The effect of batch and sex on adjusted
methylation values of probes present in the three batches
after quality control (n= 744,227) was tested for asso-
ciation with the PCs estimated in the overall sample.
Evidence of clustering according to batch was visually
detected and statistically confirmed with a significant
association of PC1 with batch (P-value < 2.20E−16).
Given that detailed smoking information was not
available for each individual, an individual smoking score
(continuous measure) was generated based on DNA
methylation sites known to be associated with current
smoking using a method developed by Elliot and collea-
gues39. To account for methylation differences between
cell types, we estimated the cell-type composition using
the estimateCellCounts function of the FlowSorted.
Blood.450k R package40.
Probe-wise differential methylation analysis was per-
formed using the lmFit function of the limma R pack-
age41. Each CpG site was tested individually in a linear
regression model with normalized, corrected beta values
as the dependent variable and ADHD status as indepen-
dent predictor, including covariates for sex, age, batch,
smoking score and cell-type composition. Age was
included as covariate in all the analysis, since it was sig-
nificantly different between cases and controls. Multiple
testing corrections were applied using false discovery rate
(FDR) with a cut-off of 5%42. The qqman R package was
used to generate the Manhattan plot.
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The post-hoc power analysis in our sample calculated
with the EPIC array online tool (https://epigenetics.essex.
ac.uk/shiny/EPICDNAmPowerCalcs/)43 using the default
significance threshold (P-value < 9.42E−08) showed that
6.12% of sites had > 90% power to detect a mean
methylation difference of 1%.
At the differentially methylated CpG site, we tested the
association between DNA methylation and the exposure
to at least one stressful life event, and to each stressful life
event separately using the lmFit function of the limma R
package. As 17 stressful life events were tested, Bonferroni
correction was set at P < 2.94E−03. We also tested the
correlation between the number of stressful life events
(sum of overall stressful life events and also separated in
pre- and post-natal periods) and DNA methylation levels
using Spearman’s correlation.
To identify differentially methylated regions (DMRs),
we used the Python module comb-p44 to group spatially
correlated CpG sites with a seed of P-value < 0.01 and 500
base pairs (bp) as the maximum distance. DMR P-values
were corrected for multiple testing using the Šidák cor-
rection45 and significant regions were defined as those
with at least two probes and an adjusted P-value < 0.05.
DMRs were mapped to genes using the interface provided
by the minfi R package or the UCSC Genome Browser to
identify the closest gene when no genes were mapped to a
region (https://genome.ucsc.edu/cgi-bin/hgGateway).
Sensitivity analyses were conducted with the same
parameters described above for the probe-wise and
regional analyses excluding smoking score as covariate in
the model.
DNA methylation analysis based on ADHD diagnosis
controlling for ADHD polygenic burden
Bioinformatic and statistical analyses
ADHD polygenic burden was inferred using a Polygenic
Risk Score (PRS) built in a subset of 195 individuals with
genotype data available, from three different genotyping
waves (Illumina HumanOmni1-Quad BeadChip (n= 3),
Illumina HumanOmni2.5-8 BeadChip (n= 29) and Infi-
nium™ Global Screening Array-24 v2.0 (n= 163) (Illu-
mina, San Diego, CA, USA), using summary statistics of
the largest GWAS-MA performed to date on ADHD4,
with different P-value thresholds ((PT) < 1e−04, 5e−04,
0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1). None of
the samples used in this study were included in this
GWAS-MA4, and thus did not contribute to defining the
variants included in the PRS.
In this subset of 195 individuals, sensitivity analyses for
the differentially methylated sites and regions were con-
ducted with the same parameters used in the original
EWAS but including the PRS explaining the most var-
iance (Nagelkerke’s R2) as an additional covariate to
control for ADHD polygenic risk burden.
ADHD PRSs for each individual were generated with
PRSice2 (https://choishingwan.github.io/PRSice/) includ-
ing sex and the first five PCs as covariates in the model.
To set an empirical threshold for the best-fit PRS, 1,000
permutations were run. Information about the pre-
imputation quality control at individual and SNP level
for the 195 individuals in the target sample and about
the phasing and imputation software used is described
elsewhere29. The European ancestry panel of the 1000
Genomes Project was considered as reference for
the imputation (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/)
and best guess genotypes were filtered by excluding var-
iants with MAF < 0.05, missing rate>0.01, Hardy-
Weinberg Equilibrium (P < 1.00E−06). Ambiguous
strand and multiallelic variants were removed and inde-
pendent SNPs (obtained using the clumping parameters
p1= 1, p2= 1, r2= 0.2, kb=250 in PLINK1.946) present
in all individuals were included (n= 37,527).
Enrichment analyses
We assessed whether probes in different categories: (i)
showing a statistically significant proportion of methyla-
tion variance explained by additive genetic effects as
reported by Zeng et al.47; (ii) probes identified in previous
EWASs on exposure to adverse live events48–50; (iii)
probes identified in previous EWASs on ADHD21,22 or
ADHD symptoms6,9 or (iv) probes located in ADHD-
associated loci identified through GWAS4,29,51 showed, on
average, a stronger association with adult ADHD than
other methylation sites by regressing our EWAS test
statistics (Zscore) on each CpG category as described by
van Dongen et al. 9:
jZscorej ¼ Interceptþ βcategory x  category x;
where |Zscore| represents the absolute value of the Zscore
from our EWAS on adult ADHD, category x represents
whether a CpG belongs or not to a specific category and
βcategory x represents the effect estimate for that category.
A CpG was assigned to a category if it was associated to
the phenotype of interest according to the P-value
thresholds shown in Supplementary Table 1 [excel file].
For GWAS, we considered CpG sites within windows of
10 kb, 100 kb, and 1Mb around significant variants
(Supplementary Table 1 [excel file]). For each enrichment
test, bootstrap standard errors were computed with 2,000
bootstraps using the “simpleboot” R package. Bonferroni
correction was applied for multiple comparison correc-
tion (PBootstrap < 3.85E−03; accounting for the 13 analyses
conducted).
We also tested for enrichment of regulatory domains,
ontological categories and pathways, using CpG sites with
P-value<1.00E−05 in our results. For the enrichment
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analysis of regulatory domains, ontological categories and
pathways, probes were annotated with the Illumina
Human EPIC array annotation R package (“IlluminaHu-
manMethylationEPICanno.ilm10b2.hg19”). The enrich-
ment analyses for transcription factor binding sites
(TFBS) and DNase I hypersensitive sites (DHS) from the
ENCODE project52 were performed using a two-sided
Fisher’s 2×2 exact test. The enrichment analyses for GO
terms and KEGG, Reactome or Biocarta pathways were
assessed using the gsameth function of the missMethyl R
package53. Gene sets denoting canonical pathways were
downloaded from MSigDB (http://www.broadinstitute.
org/gsea/msigdb), which integrates Kyoto Encyclopedia
of Genes and Genomes (KEGG) (http://www.genome.jp/
kegg/), BioCarta (http://www.biocarta.com/), Reactome
(https://reactome.org/) and Gene Ontology (GO) (http://
www.geneontology.org/) resources.
The datasets for this article are not publicly available
because of limitations in ethical approvals and the sum-
mary data will be available upon request.
Results
Our sample consisted of 103 cases and 100 controls
after quality control. The distribution of sexes was not
significantly different between groups (χ2= 2.60, P=
0.11), with 56% and 45% of cases and controls being male,
respectively. Age of participants was significantly different
between cases and controls (P= 3.61E−04), with a mean
age of 31.90 (SD= 11.45) years in cases and of 37.25 (SD
= 9.47) years in controls. In the case group, 35% of par-
ticipants experienced no stressful life events, 35% were
exposed to at least one prenatal stressful life event and
54% were exposed to at least one of them after birth
(Supplementary Table 2; Supplementary Fig. 1).
We identified one differentially methylated CpG site,
cg07143296, in the EWAS (P.adj= 0.033; Fig. 1a, b; Table
1; EWAS inflation factor λ= 0.67). This CpG lies 77 bp
upstream the PCNXL3 gene and was hypermethylated in
patients, with a mean difference of 0.2% between groups
(Table 1, Fig. 2). When evaluating the effect of prenatal
and postnatal stressful life events on the methylation
patterns of ADHD subjects at this CpG site, we found no
significant differences in the methylation levels between
individuals with ADHD exposed to stressful life events
compared to those not exposed. The combined analysis of
multiple correlated CpG sites showed evidence of asso-
ciation between ADHD and methylation levels in four
genomic regions (P.adj < 0.02), with the most significant
one spanning six CpG sites and located in the DENND2D
gene (P.adj= 2.52E−07; Table 2). The smoking score was
not significantly different between cases and controls
(mean score in cases=−2.42, mean in controls=−3.34,
P= 0.05). When we excluded it from the fitted model as
a sensitivity analysis, cg07143296 (logFC= 0.0059,
P= 1.19E−07, P.adj=0.07) and the region in chromosome
11 were no longer significant and the other regions
remained significant (Table 2).
We subsequently tested whether the polygenic risk
burden for ADHD had an effect on the DNA methylation
signatures. After constructing PRSs at different P-value
thresholds from the largest GWAS-MA on ADHD in
children and adults4, the PRS explaining the most var-
iance in our sample was found for PT= 0.001 (NSNPs=
490, R2= 0.052, Pperm= 0.029), and was significantly
higher in ADHD patients than controls (P= 3.10E−03;
Supplementary Fig. 2). After adding it as a covariate to the
model fitted for the EWAS, we found that the cg07143296
CpG site (logFC= 0.066, P= 1.60E−08, P.adj=0.012) and
three of the four genomic regions identified remained
significant (Table 2).
We then tested whether CpG sites whose methylomic
variation is mainly explained by additive genetic effects
showed, on average, a stronger association with adult
ADHD than other methylation sites included in the array,
and found a significant enrichment of signal for adult
ADHD among them (PBootstrap= 2.39E−04). In addition,
when we assessed the overlap between genetic and epi-
genetic signatures of ADHD, we found suggestive evi-
dence of overlap between our EWAS results and probes
annotated to ADHD-associated loci in the largest GWAS
meta-analyses on ADHD across the lifespan or GWAS-
MA on ADHD symptoms in children (PBootstrap= 6.75E
−03 and PBootstrap= 1.36E−02, respectively), but not with
results of previous GWAS-MA on ADHD conducted
separately in adults or children (Supplementary Table 1
[excel file]). We also considered CpG sites differentially
methylated in previous EWAS on individuals exposed to
adverse life events, on clinical ADHD or on ADHD
symptoms and found that CpG sites previously associated
with current vs never smoking and with maternal smok-
ing showed a highly significant enrichment of signal for
adult ADHD (PBootstrap= 9.03E−18 and PBootstrap= 4.62E
−14, respectively) (Supplementary Table 1 [excel file]).
However, no overlap was detected with findings of pre-
vious EWASs on ADHD, on ADHD symptoms and on
physical/emotional neglect or abuse (Supplementary
Table 1 [excel file]).
When we focused on the top 15 differentially methy-
lated CpG sites (P < 1.00E−05) in our EWAS, we found
no enrichment of regulatory domains (TFBS and DHS)
from the ENCODE project52 nor ontological categories or
pathways from GO terms, KEGG, Reactome or Biocarta
(Supplementary Table 3 [excel file]).
Discussion
To the best of our knowledge, this is the first study
evaluating DNA methylation signatures in a clinical
sample of adults with ADHD and testing whether
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smoking status, polygenic risk burden for ADHD or
exposure to stressful life events had an impact on the
methylation signatures identified.
Methylation differences were found in regions that
include genes related to cancer and pulmonary function
(DENND2D)54,55, neuroticism and regulation of histone
acetylation dynamics (PWWP2B)56,57 or regulation of
immune signaling (UBASH3A)58. We also identified a
CpG site (cg07143296) significantly hypermethylated in
ADHD, located close to PCNXL3, a gene related to
autoimmune diseases59. Although not achieving sig-
nificance after multiple comparison correction, CpG sites
in ADHD-related genes were found among the top ten
signals of the EWAS, including CREM, which has been
previously associated with impulsivity, hyperactivity,
anxiety-like behavior, circadian rhythmicity and drug
addiction60–62, ADK, whose deficiency may result in
altered dopaminergic function, attentional impairment,
and learning impairments63,64, or LAT, whose genetic
variation has been associated with educational
attainment65.
The lack of overlap between our EWAS results and
those from previous EWASs on ADHD in child-
hood6,10,11,20,22 is in line with the fact that genome-wide
DNA methylation is highly age dependent34. Contrary to
some risk factors stably involved in ADHD throughout
the lifespan, DNA methylation is developmental-stage
specific and hence the patterns contributing to ADHD
susceptibility may differ over time. The absence of overlap
between our results and findings from previous EWASs
Fig. 1 Results of the epigenome-wide association study. a Manhattan plot. Horizontal line indicates 5% FDR significance threshold (P-
value=6.72E−08). b Quantile-quantile plot.
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on ADHD in the adulthood period9,21 could be ascribed to
differences in the characteristics of the samples and on the
array used (clinical vs population-based samples and EPIC
vs Infinium Human Methylation 450K array9), to random
variation and limited statistical power or, as previously
suggested by Meijer et al.21, to the fact that the epigenetic
effects identified may not be those with the strongest
effect sizes on the phenotype21.
Results on the relationship between genetic and epige-
netic signatures in ADHD were not conclusive. We found
enrichment of signal for adult ADHD in CpGs whose
methylation variance is mainly explained by additive
genetic effects47 and suggestive evidence of enrichment in
loci described in the largest GWAS-MA on ADHD4 and
on ADHD symptoms51. However, no evidence was found
for overlap between our EWAS results and loci from
smaller GWAS-MAs on ADHD28 or for a substantial
effect of the polygenic burden for ADHD on the methy-
lation patterns identified. These inconsistent results
should be interpreted in the context of the limited sta-
tistical power of the EWAS and warrant further
investigation.
Our EWAS findings do not seem to be driven by an
effect of current smoking since they were significant when
we adjusted the model for it. When excluding smoking
status from the model, we did not detect an effect of
methylation on ADHD through smoking for cg07143296
or for the region in chromosome 11 but we cannot rule
out a mediating effect for the remaining regions as their
signal becomes more significant. Although bearing in
mind that we used an estimated smoking score that might
be a less accurate tool than clinical data, it has been
postulated as a valid marker for current tobacco
exposure13,39.
We also report preliminary data supporting overlap
between epigenetic signatures of ADHD and smoking-
related traits or behaviors. Enrichment of top-ranking
CpGs from previous EWASs on smoking behavior49 or
maternal smoking50 was obtained. In addition, methyla-
tion differences were identified in regions lying in or near
genes (such as DENND2D or PWWP2B) related to phe-
notypes where tobacco exposure is a key risk factor66–68,
and maternal smoking, which increases risk of ADHD in
the offspring69–71, was the most frequently prenatal
stressful life event reported by participants with ADHD.
To note, sixty-five percent of individuals with ADHD
reported having been exposed to stressful life events, a
circumstance that has been associated with the persis-
tence of the disorder into adulthood72. Extreme familial
stress was found among the most frequently reported
postnatal exposures in individuals with ADHD, which is
not surprising given that the presence of ADHD has been
associated to varying degrees of disturbances in family
and marital functioning73–75. However, no effect of
stressful live events on DNA methylation patterns was
found in ADHD subjects. Given that our study lacked data
on exposure to stressful live events in controls, larger
studies including cases and controls are needed to
understand the impact of environmental factors on DNA
methylation patterns associated with ADHD.
The results of the present study should be interpreted in
the context of several limitations. First, the limited sample
size of the present EWAS, which should be viewed as a
pilot study whose findings await further replication. Sec-
ond, our study design allowed the assessment of methy-
lation patterns in a restricted clinical sample of
medication-naïve subjects with no comorbid disorders.
This design may have facilitated the identification of novel
epigenetic signatures, which may not have been possible
using a broader recruitment strategy. However, given that
patients under medication and/or with lifetime comor-
bidities were excluded and this group accounts for a not
negligible proportion of the overall ADHD group, further
studies in larger samples including cases and controls
meeting common inclusion criteria, more relaxed in
terms of medication or comorbid disorders, will be
required to clarify whether the results obtained could be
generalized to a more realistic clinical situation. Third, the
low inflation factor obtained indicates that the distribu-
tion of effect sizes in the present EWAS were not driven
by systematic biases but also suggests that our study had
limited statistical power and that the data may have been
overcorrected, which may have prevented us from
detecting methylation signatures with small effect sizes.
Fig. 2 CpG‐specific DNA methylation levels. Boxplot showing the
levels of DNA methylation in cases and controls at cg07143296.
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And fourth, peripheral tissues used generally as proxies
have limited utility for inferring variation in the brain76,
although these novel signatures identified in blood might
be used as biomarkers for the disorder.
In summary, we conducted the largest study assessing
DNA methylation signatures in a clinical sample of adult
patients with ADHD. Our results suggest that ADHD
polygenic risk burden or current smoking status do not
change substantially the methylomic variation between
cases and controls, suggest an overlap between epigenetic
signatures of ADHD and smoking-related traits, and point
to an overlap between genetic and epigenetic signatures in
ADHD. These results emphasize the need of additional
efforts in larger samples and the inclusion of stressful life
events in future studies to clarify the role of epigenetic
mechanisms and environmental risk factors on ADHD
across the lifespan.
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